de Winter Maria A, Xu Yan, Stacey Dawn, Wells Philip S
Department of Acute Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Internal Medicine, Diakonessenhuis, Utrecht, The Netherlands.
Res Pract Thromb Haemost. 2024 Mar 1;8(2):102360. doi: 10.1016/j.rpth.2024.102360. eCollection 2024 Feb.
Contemporary guidelines recommend extended-duration anticoagulation among patients with a first unprovoked venous thromboembolism (VTE). Little is known about whether this recommendation aligns with patient values after a bleeding complication.
To explore the experiences, values, and decisional needs of patients with unprovoked VTE related to extended-duration treatment after an anticoagulant-associated bleed.
In this descriptive, qualitative study, face to face online semistructured interviews were conducted with patients with unprovoked VTE who had experienced bleeding and continued anticoagulant treatment in one academic hospital in Canada. Data were analyzed using directed content analysis to identify themes. Themes were mapped onto the Ottawa Decisional Support Framework to identify decisional needs.
Between September and December 2021, 14 patients were interviewed (age 41-69 years; 9 females). Many patients were not aware of the option to stop anticoagulation and had limited understanding of the decision about treatment duration. Despite the negative quality-of-life impact of clinically relevant bleeding during VTE treatment, the majority continued anticoagulation due to emotional trauma of VTE diagnosis, a perception that bleeding would be more manageable than VTE recurrence, a desire to maintain a connection to subspecialty care or non-VTE related benefits (eg, cancer diagnosis, protection from COVID-19). Patients' decisional needs included lack of choice awareness, inadequate support for participation, lack of personalized risk stratification, and inadequate information on monitoring and managing heavy menstrual bleeding.
Despite the impact of anticoagulant-associated bleeding on quality of life, patients preferred continuing with anticoagulation for reasons extending beyond secondary VTE prevention. Effective decision-support interventions are needed to address unmet decisional needs.
当代指南建议对首次发生的不明原因静脉血栓栓塞症(VTE)患者进行长期抗凝治疗。对于这一建议在出血并发症发生后是否符合患者价值观,人们知之甚少。
探讨不明原因VTE患者在抗凝相关出血后与长期治疗相关的经历、价值观和决策需求。
在这项描述性定性研究中,对加拿大一家学术医院中经历过出血且仍在继续抗凝治疗的不明原因VTE患者进行了面对面的在线半结构化访谈。使用定向内容分析法对数据进行分析以确定主题。将主题映射到渥太华决策支持框架上以确定决策需求。
在2021年9月至12月期间,对14名患者进行了访谈(年龄41 - 69岁;9名女性)。许多患者不知道可以选择停止抗凝,并且对治疗时长的决策理解有限。尽管VTE治疗期间临床相关出血对生活质量有负面影响,但大多数患者由于VTE诊断带来的情感创伤、认为出血比VTE复发更易控制、希望保持与专科护理的联系或获得与VTE无关的益处(如癌症诊断、预防新冠病毒)而继续抗凝治疗。患者的决策需求包括缺乏选择意识、参与支持不足、缺乏个性化风险分层以及关于监测和处理月经过多的信息不足。
尽管抗凝相关出血对生活质量有影响,但患者出于二级VTE预防之外的原因更倾向于继续抗凝治疗。需要有效的决策支持干预措施来满足未得到满足的决策需求。